ArticleMolecular biology reports2024

Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1.

Esin Guvenir Celik et al.PubMed ↗Publisher ↗

No numbers read from the abstract.